Hepa definitely has a seat at the adult table (we sit at the kids' table). They will be a player in negotiations, most likely. But all of their rights in Asia, and their RVX investment and stock holdings don't mean a hill of beans if apabetalone and other molecules never make it out of the pantry. Is Hepa prepared to buy controlling interest, and foot the future development costs alone??

So, a "complementary" BP partner who can play nice and find a "fit" with Hepa may be ideal, sharing common interests, that fit together geographically for manufacturing and distribution interests.

Unless, just a simply overwhelming ROI on RVX pps as part of a deal just makes them happy enough to push back from the buffett table. That would have to be a significant multiple of $2.67 presumably?

It will be very interesting to see how this eventually works out ...